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Key Points
Question
What are the characteristics, clinical presentation, and outcomes of patients hospitalized with coronavirus
disease 2019 (COVID-19) in the US?
Findings
In this case series that included 5700 patients hospitalized with COVID-19 in the New York City area, the
most common comorbidities were hypertension, obesity, and diabetes. Among patients who were
discharged or died (n = 2634), 14.2% were treated in the intensive care unit, 12.2% received invasive
mechanical ventilation, 3.2% were treated with kidney replacement therapy, and 21% died.
Meaning
This study provides characteristics and early outcomes of patients hospitalized with COVID-19 in the New
York City area.

Abstract
Importance
There is limited information describing the presenting characteristics and outcomes of US patients
requiring hospitalization for coronavirus disease 2019 (COVID-19).
Objective
To describe the clinical characteristics and outcomes of patients with COVID-19 hospitalized in a US
health care system.
Design, Setting, and Participants
Case series of patients with COVID-19 admitted to 12 hospitals in New York City, Long Island, and
Westchester County, New York, within the Northwell Health system. The study included all sequentially
hospitalized patients between March 1, 2020, and April 4, 2020, inclusive of these dates.
Exposures
Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive result on
polymerase chain reaction testing of a nasopharyngeal sample among patients requiring admission.
Main Outcomes and Measures
Clinical outcomes during hospitalization, such as invasive mechanical ventilation, kidney replacement
therapy, and death. Demographics, baseline comorbidities, presenting vital signs, and test results were also
collected.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177629/?report=printable
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Results
A total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0107 years]; 39.7% female). The most common comorbidities were hypertension (3026; 56.6%), obesity
(1737; 41.7%), and diabetes (1808; 33.8%). At triage, 30.7% of patients were febrile, 17.3% had a
respiratory rate greater than 24 breaths/min, and 27.8% received supplemental oxygen. The rate of
respiratory virus co-infection was 2.1%. Outcomes were assessed for 2634 patients who were discharged
or had died at the study end point. During hospitalization, 373 patients (14.2%) (median age, 68 years
[IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive
mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. As
of April 4, 2020, for patients requiring mechanical ventilation (n = 1151, 20.2%), 38 (3.3%) were
discharged alive, 282 (24.5%) died, and 831 (72.2%) remained in hospital. The median postdischarge
follow-up time was 4.4 days (IQR, 2.2-9.3). A total of 45 patients (2.2%) were readmitted during the study
period. The median time to readmission was 3 days (IQR, 1.0-4.5) for readmitted patients. Among the
3066 patients who remained hospitalized at the final study follow-up date (median age, 65 years [IQR, 5475]), the median follow-up at time of censoring was 4.5 days (IQR, 2.4-8.1).
Conclusions and Relevance
This case series provides characteristics and early outcomes of sequentially hospitalized patients with
confirmed COVID-19 in the New York City area.

Introduction
The first confirmed case of coronavirus disease 2019 (COVID-19) in the US was reported from
Washington State on January 31, 2020.1 Soon after, Washington and California reported outbreaks, and
cases in the US have now exceeded total cases reported in both Italy and China.2 The rate of infections in
New York, with its high population density, has exceeded every other state, and, as of April 20, 2020, it
has more than 30% of all of the US cases.3
Limited information has been available to describe the presenting characteristics and outcomes of US
patients requiring hospitalization with this illness. In a retrospective cohort study from China, hospitalized
patients were predominantly men with a median age of 56 years; 26% required intensive care unit (ICU)
care, and there was a 28% mortality rate.4 However, there are significant differences between China and
the US in population demographics,5 smoking rates,6 and prevalence of comorbidities.7
This study describes the demographics, baseline comorbidities, presenting clinical tests, and outcomes of
the first sequentially hospitalized patients with COVID-19 from an academic health care system in New
York.

Methods
The study was conducted at hospitals in Northwell Health, the largest academic health system in New
York, serving approximately 11 million persons in Long Island, Westchester County, and New York City.
The Northwell Health institutional review board approved this case series as minimal-risk research using
data collected for routine clinical practice and waived the requirement for informed consent. All
consecutive patients who were sufficiently medically ill to require hospital admission with confirmed
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by positive result on polymerase
chain reaction testing of a nasopharyngeal sample were included. Patients were admitted to any of 12
Northwell Health acute care hospitals between March 1, 2020, and April 4, 2020, inclusive of those dates.
Clinical outcomes were monitored until April 4, 2020, the final date of follow-up.
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Data were collected from the enterprise electronic health record (Sunrise Clinical Manager; Allscripts)
reporting database, and all analyses were performed using version 3.5.2 of the R programming language
(R Project for Statistical Computing; R Foundation). Patients were considered to have confirmed infection
if the initial test result was positive or if it was negative but repeat testing was positive. Repeat tests were
performed on inpatients during hospitalization shortly after initial test results were available if there was a
high clinical pretest probability of COVID-19 or if the initial negative test result had been judged likely to
be a false-negative due to poor sample collection. Transfers from one in-system hospital to another were
merged and considered as a single visit. There were no transfers into or out of the system. For patients with
a readmission during the study period, data from the first admission are presented.
Data collected included patient demographic information, comorbidities, home medications, triage vitals,
initial laboratory tests, initial electrocardiogram results, diagnoses during the hospital course, inpatient
medications, treatments (including invasive mechanical ventilation and kidney replacement therapy), and
outcomes (including length of stay, discharge, readmission, and mortality). Demographics, baseline
comorbidities, and presenting clinical studies were available for all admitted patients. All clinical
outcomes are presented for patients who completed their hospital course at study end (discharged alive or
dead). Clinical outcomes available for those in hospital at the study end point are presented, including
invasive mechanical ventilation, ICU care, kidney replacement therapy, and length of stay in hospital.
Outcomes such as discharge disposition and readmission were not available for patients in hospital at study
end because they had not completed their hospital course. Home medications were reported based on the
admission medication reconciliation by the inpatient-accepting physician because this is the most reliable
record of home medications. Final reconciliation has been delayed until discharge during the current
pandemic. Home medications are therefore presented only for patients who have completed their hospital
course to ensure accuracy.
Race and ethnicity data were collected by self-report in prespecified fixed categories. These data were
included as study variables to characterize admitted patients. Initial laboratory testing was defined as the
first test results available, typically within 24 hours of admission. For initial laboratory testing and clinical
studies for which not all patients had values, percentages of total patients with completed tests are shown.
The Charlson Comorbidity Index predicts 10-year survival in patients with multiple comorbidities and was
used as a measure of total comorbidity burden.8 The lowest score of 0 corresponds to a 98% estimated 10year survival rate. Increasing age in decades older than age 50 years and comorbidities, including
congestive heart disease and cancer, increase the total score and decrease the estimated 10-year survival. A
total of 16 comorbidities are included. A score of 7 points and above corresponds to a 0% estimated 10year survival rate. Acute kidney injury was identified as an increase in serum creatinine by 0.3 mg/dL or
more (≥26.5 μmol/L) within 48 hours or an increase in serum creatinine to 1.5 times or more baseline
within the prior 7 days compared with the preceding 1 year of data in acute care medical records. This was
based on the Kidney Disease: Improving Global Outcomes (KDIGO) definition.9 Acute hepatic injury was
defined as an elevation in aspartate aminotransferase or alanine aminotransferase of more than 15 times the
upper limit of normal.

Results
A total of 5700 patients were included (median age, 63 years [interquartile range {IQR}, 52-75; range, 0107 years]; 39.7% female) (Table 1). The median time to obtain polymerase chain reaction testing results
was 15.4 hours (IQR, 7.8-24.3). The most common comorbidities were hypertension (3026, 56.6%),
obesity (1737, 41.7%), and diabetes (1808, 33.8%). The median score on the Charlson Comorbidity Index
was 4 points (IQR, 2-6), which corresponds to a 53% estimated 10-year survival and reflects a significant
comorbidity burden for these patients. At triage, 1734 patients (30.7%) were febrile, 986 (17.3%) had a
respiratory rate greater than 24 breaths/min, and 1584 (27.8%) received supplemental oxygen (Table 2 and
Table 3). The first test for COVID-19 was positive in 5517 patients (96.8%), while 183 patients (3.2%) had
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177629/?report=printable
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a negative first test and positive repeat test. The rate of co-infection with another respiratory virus for those
tested was 2.1% (42/1996). Discharge disposition by 10-year age intervals of all 5700 study patients is
included in Table 4. Length of stay for those who died, were discharged alive, and remained in hospital are
presented as well. Among the 3066 patients who remained hospitalized at the final study follow-up date
(median age, 65 years [IQR 54-75]), the median follow-up at time of censoring was 4.5 days (IQR, 2.48.1). Mortality was 0% (0/20) for male and female patients younger than 20 years. Mortality rates were
higher for male compared with female patients at every 10-year age interval older than 20 years.
Outcomes for Patients Who Were Discharged or Died
Among the 2634 patients who were discharged or had died at the study end point, during hospitalization,
373 (14.2%) were treated in the ICU, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%)
were treated with kidney replacement therapy, and 553 (21%) died (Table 5). As of April 4, 2020, for
patients requiring mechanical ventilation (n = 1151, 20.2%), 38 (3.3%) were discharged alive, 282 (24.5%)
died, and 831 (72.2%) remained in hospital. Mortality rates for those who received mechanical ventilation
in the 18-to-65 and older-than-65 age groups were 76.4% and 97.2%, respectively. Mortality rates for those
in the 18-to-65 and older-than-65 age groups who did not receive mechanical ventilation were 1.98% and
26.6%, respectively. There were no deaths in the younger-than-18 age group. The overall length of stay
was 4.1 days (IQR, 2.3-6.8). The median postdischarge follow-up time was 4.4 days (IQR, 2.2-9.3). A total
of 45 patients (2.2%) were readmitted during the study period. The median time to readmission was 3 days
(IQR, 1.0-4.5). Of the patients who were discharged or had died at the study end point, 436 (16.6%) were
younger than age 50 with a score of 0 on the Charlson Comorbidity Index, of whom 9 died.
Outcomes by Age and Risk Factors
For both patients discharged alive and those who died, the percentage of patients who were treated in the
ICU or received invasive mechanical ventilation was increased for the 18-to-65 age group compared with
the older-than-65 years age group (Table 5). For patients discharged alive, the lowest absolute lymphocyte
count during hospital course was lower for progressively older age groups. For patients discharged alive,
the readmission rates and the percentage of patients discharged to a facility (such as a nursing home or
rehabilitation), as opposed to home, increased for progressively older age groups.
Of the patients who died, those with diabetes were more likely to have received invasive mechanical
ventilation or care in the ICU compared with those who did not have diabetes (eTable 1 in the
Supplement). Of the patients who died, those with hypertension were less likely to have received invasive
mechanical ventilation or care in the ICU compared with those without hypertension. The percentage of
patients who developed acute kidney injury was increased in the subgroups with diabetes compared with
subgroups without those conditions.
Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use
Home medication reconciliation information was available for 2411 (92%) of the 2634 patients who were
discharged or who died by the study end. Of these 2411 patients, 189 (7.8%) were taking an angiotensinconverting enzyme inhibitor (ACEi) at home and 267 (11.1%) were taking an angiotensin II receptor
blocker (ARB) at home. The median number of total home medications was 3 (IQR, 0-7). Outcomes for
subgroups of patients with hypertension by use of ACEi or ARB home medication are shown in eTable 2
in the Supplement. Numbers provided for total patients taking ACEi or ARB therapy in eTable 2 in the
Supplement are provided only for patients who also had a diagnosis of hypertension.
Of the patients taking an ACEi at home, 91 (48.1%) continued taking an ACEi while in the hospital and
the remainder discontinued this type of medication during their hospital visit. Of the patients taking an
ARB at home, 136 (50.1%) continued taking an ARB while in the hospital and the remainder discontinued
taking this type of medication during their hospital visit. Of patients who were not prescribed an ACEi or
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177629/?report=printable
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ARB at home, 49 started treatment with an ACEi and 58 started treatment with an ARB during their
hospitalization. Mortality rates for patients with hypertension not taking an ACEi or ARB, taking an ACEi,
and taking an ARB were 26.7%, 32.7%, and 30.6%, respectively.

Discussion
To our knowledge, this study represents the first large case series of sequentially hospitalized patients with
confirmed COVID-19 in the US. Older persons, men, and those with pre-existing hypertension and/or
diabetes were highly prevalent in this case series and the pattern was similar to data reported from China.4
However, mortality rates in this case series were significantly lower, possibly due to differences in
thresholds for hospitalization. This study reported mortality rates only for patients with definite outcomes
(discharge or death), and longer-term study may find different mortality rates as different segments of the
population are infected. The findings of high mortality rates among ventilated patients are similar to
smaller case series reports of critically ill patients in the US.10
ACEi and ARB medications can significantly increase mRNA expression of cardiac angiotensinconverting enzyme 2 (ACE2),11 leading to speculation about the possible adverse, protective, or biphasic
effects of treatment with these medications.12 This is an important concern because these medications are
the most prevalent antihypertensive medications among all drug classes.13 However, this case series
design cannot address the complexity of this question, and the results are unadjusted for known
confounders, including age, sex, race, ethnicity, socioeconomic status indicators, and comorbidities such as
diabetes, chronic kidney disease, and heart failure.
Mortality rates are calculated only for patients who were discharged alive or died by the study end point.
This biases our rates toward including more patients who died early in their hospital course. Most patients
in this study were still in hospital at the study end point (3066, 53.8%). We expect that as these patients
complete their hospital course, reported mortality rates will decline.
Limitations
This study has several limitations. First, the study population only included patients within the New York
metropolitan area. Second, the data were collected from the electronic health record database. This
precluded the level of detail possible with a manual medical record review. Third, the median
postdischarge follow-up time was relatively brief at 4.4 days (IQR, 2.2-9.3). Fourth, subgroup descriptive
statistics were unadjusted for potential confounders. Fifth, clinical outcome data were available for only
46.2% of admitted patients. The absence of data on patients who remained hospitalized at the final study
date may have biased the findings, including the high mortality rate of patients who received mechanical
ventilation older than age 65 years.

Conclusions
This case series provides characteristics and early outcomes of sequentially hospitalized patients with
confirmed COVID-19 in the New York City area.

Notes

Supplement.

eTable 1. Clinical Measures and Outcomes for Patients Discharged Alive or Dead at Study End
Point – By Comorbidity
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eTable 2. Clinical Measures and Outcomes for Patients Discharged Alive or Dead at Study End
Point – By Home Medication
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Table 1.
Baseline Characteristics of Patients Hospitalized With COVID-19
No. (%)
Demographic information
Total No.

5700

Age, median (IQR) [range], y

63 (52-75) [0-107]

Sex
Female

2263 (39.7)

Male
a
Race

3437 (60.3)

No.

5441

African American

1230 (22.6)

Asian

473 (8.7)

White

2164 (39.8)

Other/multiracial
a
Ethnicity

1574 (28.9)

No.

5341

Hispanic

1230 (23)

Non-Hispanic

4111 (77)

Preferred language non-English

1054 (18.5)

Insurance
Commercial

1885 (33.1)

Medicaid

1210 (21.2)

Medicare

2415 (42.4)

Self-pay
b
Other

95 (1.7)
95 (1.7)

Comorbidities
Total No.

5700

Cancer

320 (6)

Cardiovascular disease
Hypertension

3026 (56.6)

Coronary artery disease

595 (11.1)

Open in a separate window
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared);
COVID-19, coronavirus disease 2019; IQR, interquartile range.
a

Race and ethnicity data were collected by self-report in prespecified fixed categories.
Other insurance includes military, union, and workers’ compensation.
c
Assessed based on a diagnosis of chronic kidney disease in medical history by International Statistical Classification
of Diseases and Related Health Problems, Tenth Revision (ICD-10) coding.
b

d
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177629/?report=printable

11/20

9/16/2020

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
d

Assessed based on a diagnosis of end-stage kidney disease in medical history by ICD-10 coding.
Assessed based on a diagnosis of diabetes mellitus and includes diet-controlled and non–insulin-dependent diabetes.
f
Comorbidities listed here are defined as medical diagnoses included in medical history by ICD-10 coding. These
include, but are not limited to, those presented in the table.
g
Charlson Comorbidity Index predicts the 10-year mortality for a patient based on age and a number of serious
comorbid conditions, such as congestive heart failure or cancer. Scores are summed to provide a total score to predict
mortality. The median score of 4 corresponds to a 53% estimated 10-year survival and reflects a significant
comorbidity burden for these patients.
e
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Table 2.
Presentation Vitals and Laboratory Results of Patients Hospitalized With COVID-19
a
Triage vitals

No. (%)

No.

Reference
ranges

Temperature >38 °C

1734 (30.7)

Temperature, median (IQR), °C

37.5 (36.9-38.3)

5644

Oxygen saturation
<90%

1162 (20.4)

% Median (IQR)

95 (91-97)

Received supplemental oxygen at triage

1584 (27.8)

5693

Respiratory rate >24 breaths/min

986 (17.3)

5695

5693

Heart rate
≥100 beats/min

2457 (43.1)

Median (IQR)

97 (85-110)

a
Initial laboratory measures, median (IQR)
9
White blood cell count, ×10 /L
9
Absolute count, ×10 /L

7.0 (5.2-9.5)

5680 3.8-10.5

Neutrophil

5.3 (3.7-7.7)

5645 1.8-7.4

Lymphocyte

0.88 (0.6-1.2)

5645 1.0-3.3

9
Lymphocyte, <1000 × 10 /L

3387 (60)

Sodium, mmol/L

136 (133-138)

5645 135-145

Aspartate aminotransferase, U/L

46 (31-71)

5586 10-40

Aspartate aminotransferase >40 U/L

3263 (58.4)

Alanine aminotransferase, U/L

33 (21-55)

Alanine aminotransferase >60 U/L

2176 (39.0)

Creatine kinase, U/L

171 (84-397)

2527 25-200

Venous lactate, mmol/L

1.5 (1.1-2.1)

2508 0.7-2.0

b
Troponin above test-specific upper limit of normal

801 (22.6)

3533

Brain-type natriuretic peptide, pg/mL

385.5 (106-

1818 0-99

5696

5587 10-45

1996.8)
Procalcitonin, ng/mL

0.2 (0.1-0.6)

4138 0.02-0.10

D-dimer, ng/mL

438 (262-872)

3169 0-229

Ferritin ng/mL

798 (411 1515)

4344 15 400

Open in a separate window
Abbreviations: COVID-19, coronavirus disease 2019; ECG, electrocardiogram; IQR, interquartile range; QTC,
corrected QT interval.
SI conversion factors: To convert alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase,
creatinine kinase, and lactate dehydrogenase to μkat/L, multiply by 0.0167.
aTriage vital signs, initial laboratory measures, and admission studies were selected to be included here based on

relevance to the characterization of patients with COVID-19.
b
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b

Troponin I; troponin T; and troponin T, high sensitivity are used at about equal frequency across these institutions.
For simplicity, we present the number and percentage of test results that were above the upper limit of normal for the
individual references ranges for these 3 tests.
c
QTC resulted from the automated ECG reading.
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Table 3.
Hospital Characteristics and Admission Rates
a
Hospital

No. (%)
Study admissions

North Shore University

Acute beds (March
b
occupancy), mean

Annual emergency department

(N = 5700)
1073 (18.8)

637 (92)

51 000 (34)

1151 (20.2)

517 (91)

66 000 (28)

466 (85)

93 000 (25)

visits (% admitted)

Hospital
Long Island Jewish
Medical Center
Staten Island University 674 (11.9)
Hospital
Lenox Hill Hospital

558 (9.8)

324 (75)

40 000 (29)

Southside Hospital

445 (7.8)

270 (86)

59 000 (18)

Huntington Hospital

359 (6.3)

231 (81)

40 000 (22)

Long Island Jewish

608 (10.7)

187 (86)

42 000 (21)

355 (6.2)

180 (75)

31 000 (23)

Plainview Hospital

231 (4.1)

156 (70)

24 000 (29)

Cohen Children’s

42 (0.7)

111 (78)

48 000 (14)

117 (2.1)

66 (78)

15 000 (20)

87 (1.5)

55 (70)

12 000 (21)

Forest Hills
Long Island Jewish
Valley Stream

Medical Center
Glen Cove Hospital,
nonteaching
Syosset Hospital

aTeaching hospital unless otherwise noted.

bMore than 1200 acute beds were added across the system during the month of March 2020.
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Table 4.
Discharge Disposition by 10-Year Age Intervals of Patients Hospitalized With COVID-19
Patients discharged alive or dead at study end point

Patients in
hospital at study
end point

Died, No./No.

Length of stay

Discharged alive, Length of stay

No./No.

Length

(%)

among those who

No./No. (%)

(%)

of stay,

Male

Female

0/13

0/13

died, median
a
(IQR), d

Male

Female

13/13

13/13

(100)

(100)

among those
discharged alive,
a
median (IQR), d

median
(IQR),
a
d

Age
intervals,
y
0-9

NA

2.0 (1.7-2.7)

7/33

4.3

(21.2)

(3.112.5)

10-19

0/1

0/7

NA

1/1

7/7

(100)

(100)

1.8 (1.0-3.1)

9/17

3.3

(52.9)

(2.84.3)

20-29

3/42

1/55

(7.1)

(1.8)

4.0 (0.8-7.4)

39/42

54/55

(92.9)

(98.2)

2.5 (1.8-4.0)

52/149

3.2

(34.9)

(1.96.4)

30-39

6/130

2/81

(4.6)

(2.5)

2.8 (2.4-3.6)

124/130 79/81
(95.4)

3.7 (2.0-5.8)

(97.5)

142/353

5.1

(40.2)

(2.59.0)

40-49

19/233 3/119
(8.2)

5.6 (3.0-8.4)

(2.5)

214/233 116/119 3.9 (2.3-6.1)

319/671

4.9

(91.8)

(47.5)

(2.9-

(97.5)

8.2)
50-59

40/327 13/188
(12.2)

5.9 (3.1-9.5)

(6.9)

287/327 175/188 3.8 (2.5-6.7)

594/1109 4.9

(87.8)

(53.6)

(93.1)

(2.88.0)

60-69

56/300 28/233
(18.7)

5.7 (2.6-8.2)

(12.0)

244/300 205/233 4.3 (2.5-6.8)

771/1304 5.0

(81.3)

(59.1)

(88.0)

(2.48.2)

70-79

91/254 54/197
(35.8)

5.0 (2.7-7.8)

(27.4)

163/254 143/197 4.6 (2.8-7.8)

697/1148 4.5

(64.2)

(60.7)

(72.6)

(2.3-

Open in a separate window
Abbreviations: COVID-19, coronavirus disease 2019; IQR, interquartile range; NA, not applicable.
a

Length of stay begins with admission time and ends with discharge time, time at death, or midnight on the last day of
data collection for the study. It does not include time in the emergency department.
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Table 5.
Clinical Measures and Outcomes for Patients Discharged Alive, Dead, and In Hospital at
Study End Point by Age
Clinical measure

Total

Discharged alive

discharged

<18 y 18-65 >65 y <18 18-65 >65 y <18

18-65 >65

alive and dead

(n =

y (n

(n =

y

y (n

(n =

(n =

(n =

patients (N =

32)

=

676)

(n

=

419)

14)

1565) 1487)

175

4

449

2634)
Invasive mechanical
a
ventilation

320 (12.2)

ICU care

373 (14.2)

Absolute lymphocyte

0.8 (0.5-1.14)

count at nadir, median
9
(IQR), ×10 /L

1373)
0

Died

In hospital
(n =

= 0) 134)

33

5

(2.4)

(0.7)

2

62

18

(6.3)

(4.5)

(2.7)

2.3

0.9

0.8

(1.2-

(0.7-

(0.5-

5.0)

1.2)

NA 107

378

(79.9) (41.8) (28.6) (28.7) (25.4)
NA 109

182

5

490

413

(81.3) (43.4) (35.7) (31.3) (27.8)
NA 0.5

0.5

2.0

0.7

0.6

(0.3-

(0.3-

(1.0-

(0.5-

(0.4-

1.1)

0.8)

0.8)

3.5)

1.0)

0.9)

134

417

3

1564

1486

249

2

388

457

(reference range, 1.03.3)
No.

2626

32

1371

675

b
Acute kidney injury

523 (22.2)

1

93

82

(11.1) (7.5)

(13.1)

(83.8) (68.4) (14.3) (25.5) (34.5)
117

No.

2351

8

1237

624

Kidney replacement

81 (3.2)

0

2

1

(0.1)

(0.2)

3

0

therapy
c
Acute hepatic injury

56 (2.1)

NA 98

0

(0.2)
No.

NA 43

364

8

1400

1326

35

0

82

62

(5.4)

(4.4)

21

12

(1.3)

(0.8)

(35.0) (8.8)
NA 25

28

0

(18.7) (6.7)

1371

675

134

417

3

1564

1486

2.0

3.8

4.5

NA 5.5

4.4

4.0

4.8

4.4

(1.7-

(2.3-

(2.7-

(2.9-

(2.1-

(2.4-

(2.5-

(2.3-

2.8)

6.2)

7.2)

8.4)

7.1)

6.2)

8.1)

8.0)

N/A

Outcomes
Length of stay, median
d
(IQR), d

4.1 (2.3-6.8)

Discharged alive

3.9 (2.4-6.7)

Died

4.8 (2.3-7.4)

Died

553 (21)

NA

NA

NA

NA NA

NA

NA

NA

Died, of those who did

271/2314 (11.7) NA

NA

NA

NA NA

NA

NA

NA

not receive mechanical
ventilation

Open in a separate window
Abbreviations: ICU, intensive care unit; IQR, interquartile range; NA, not applicable.
a

Policy in the system has been not to treat patients with COVID-19 with bilevel positive airway pressure and
continuous positive airway pressure out of concern for aerosolizing virus particles and therefore that information is
not reported here.
b
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b

Acute kidney injury was identified as an increase in serum creatinine by ≥0.3 mg/dL (≥26.5 mol/L) within 48 hours
or an increase in serum creatinine to ≥1.5 times baseline within the prior 7 days compared with the preceding 1 year
of data in acute care medical records. Acute kidney injury is calculated only for patients with record of baseline
kidney function data available and without a diagnosis of end-stage kidney disease.
c
Acute hepatic injury was defined as an elevation in aspartate aminotransferase or alanine aminotransferase of >15
times the upper limit of normal.
d
Length of stay begins with admission time and ends with discharge time or time of death. It does not include time in
the emergency department.
e
Data are presented here for readmission during the study period, March 1 to April 4, 2020.
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